Chairman of the Board
Mr. Hudson is a co-founder and chairman of the board of the HudsonAlpha Institute for Biotechnology, a non-profit research institute that uses biotechnology to improve human health, stimulate economic development and inspire Alabama’s youth.
An advocate for local arts, Hudson is the founder of Lowe Mill Arts and Entertainment, a 240,000 sq. ft. arts facility located on seventeen acres in an 19th century textile mill. Near downtown Huntsville Lowe Mill supports a diverse community of artisans with 180 studios open to the public.
In 1987, Hudson founded Research Genetics. Prior to merging with Invitrogen in 2000, Research Genetics had become the world’s leader in genetic linkage products and an integral partner in the Human Genome Project. Hudson has incubated multiple companies in industries ranging from genetics research to Internet services.
Earlier, Hudson, along with his father and brother co-founded Hudson Metals, a gray iron and aluminum foundry, which operated from 1970 until the company, was sold in 1982.
Prior to joining his father and brother, Hudson served as an officer in the U.S. Army Corps of Engineers and as U.S. Army aviator. During his tour of duty in Vietnam, Hudson flew many reconnaissance missions over North Vietnam, where he earned the Distinguished Flying Cross for heroism in combat.
Hudson earned a B.S. in Chemistry and a M.S. in physics from the University of Alabama. Later Hudson earned a M.S. in biology from the University of Alabama Huntsville.
Tom Main is a Partner of 7wire Ventures where he plays a key role in driving thought leadership on Health Market 2.0 and maintaining a strategic market / investment map for the overall portfolio. Tom is deeply involved in origination and digs in with the 7wire portfolio companies on strategy, product roadmap and commercialization.
Prior to joining 7wire Ventures, Tom served as U.S. Market Leader for the Oliver Wyman Health and Life Sciences practice and was the driving force behind the foundation of the Oliver Wyman Health Innovation Center. Over the last five years Tom has dedicated himself and Oliver Wyman to creating a strategic roadmap for the industry, working through the Innovation Center’s Leaders Alliance – a community of forty CEOs – to accelerate value-based care models and pivot the market from being physician centric to consumer led.
Tom also founded and led ChapterHouse, a strategic advisory business specializing in healthcare, where he excelled at thought leadership and served many of the health industry’s senior leadership teams and boards. Through Tom’s leadership, ChapterHouse became a recognized national brand and maintained a twenty five percent annual growth rate over a twelve year period. Tom merged ChapterHouse into Oliver Wyman, creating the foundation for Oliver Wyman’s healthcare practice.
Prior to starting ChapterHouse, Tom led strategy and corporate development for Aetna, working to transform the company from insurance to managed care. Tom supported a series of acquisitions and led the strategy process during the Company’s initial efforts to deploy managed care capabilities – HMOs, PPOs, PBMs and Behavior Health – into geographic markets and across funding sources. Tom also spent his early days with American Hospital Supply Corporation and Baxter Healthcare learning the product and distribution side of the business where he worked across product lines in the U.S. and in Europe.
Tom is a recognized healthcare thought leader with articles published in The Atlantic, Forbes, WIRED and Entrepreneur. He has shared his vision for Health 2.0 through his widely distributed and thought provoking white paper series; The Quiet Healthcare Revolution, The Volume to Value Revolution, The Patient to Consumer Revolution and, most recently, The Marketplace Revolution.
Tom has worked with and advised more than one hundred health and wellness organizations ranging from health systems to precision medicine. He serves on the boards of Envision and Livongo Health and the advisory boards of Alignment Healthcare and Welltok. He is also an observer of the Zest Health board.
Tom holds an MBA from Northern Illinois University and a BA in business from Miami University of Ohio.
Howard Jacob, PhD
Howard Jacob is the new Vice President of Genomic Research Center at AbbVie.
Howard was formerly the Executive Vice President for Medical Genomics and Chief Medical Genomics Officer at the HudsonAlpha Institute for Biotechnology. Howard came to HudsonAlpha from the Medical College of Wisconsin where he was the Founding Director of the Human and Molecular Genetics Center (HMGC) and Professor of Physiology and was awarded the Warren P. Knowles Chair of Genetics.
Previously, Dr. Jacob was on the faculty at Massachusetts General Hospital and Harvard Medical School. He received his Ph.D. in Pharmacology from the University of Iowa and he completed post-doctoral fellowships in functional genomics and molecular genetics/genomics at Harvard Medical School, Stanford University and the Massachusetts Institute of Technology.
In 2009, Dr. Jacob led a team of researchers at the Medical College of Wisconsin in the use of an innovative DNA sequencing technique to unravel the medical mystery of Nicholas Volker, a young boy whose life-threatening disease had baffled his doctors for years. Working with scientists and physicians at the Children’s Hospital of Wisconsin, Jacob’s team sequenced Nicholas’ DNA to diagnose his disease and recommend a course of treatment. This treatment was successful, making Nicholas the first patient to be saved by genomic sequencing.
Dr. Jacob’s passion for improving the lives of critically ill patients has been the catalyst for his determination to bring whole genome sequencing into the clinical setting to affect patient care. Under his leadership, the HMGC in Wisconsin grew from two faculty members to 22 and is one of the top funded genetic programs in the country. He now brings that same passion and expertise to HudsonAlpha to lead the new HudsonAlpha Center for Personal Genomics.
Grace Terrell MD, MMM
Dr. Grace Terrell is CEO of Envision Genomics, a company helping clinicians diagnose rare disease through the integration of genomic data into clinical care. At Envision Genomics, she is focused on the integration of precision medicine technology into population health frameworks for patients with rare, misdiagnosed, and undiagnosed disorders to improve the triple aim 100-fold. She is a national thought leader in health care innovation and delivery system reform, and a serial entrepreneur in population health outcomes driven through patient care model design, clinical and information integration , and value-based payment models.
In 1995 she and seven other physicians founded Cornerstone Health Care, a multi-specialty medical practice now part of the Wake Forest Baptist Health System. While CEO, Cornerstone grew from 42 physicians and $16 M in annual revenues to 375 providers and $250 M in revenues and won AMGA’s prestigious Acclaim Award, had the best performing MSSP Track 1 ACO in the country, was the first system-wide Patient Centered Medical Home in North Carolina, and was one of the first organizations to make the “move to value” by lowering the cost of care and improving its quality for the sickest, most vulnerable patients in various care models by 13-20%.
In 2013, Dr. Terrell launched CHESS, a population health management company that brought the innovations of the Cornerstone care model redesign process to a wider group of health care systems. She served as CEO of CHESS until it was acquired by LabCorp and Wake Forest Baptist Health in 2016. CHESS currently has greater than 120,000 lives under management in various risk-based contracts.
Dr. Terrell currently serves on the U.S. Department of Health and Human Services’ Physician-Focused Payment Model Technical Advisory Committee, the Board of Directors of the American Medical Group Association, and the Oliver Wyman Health Innovation Center’s Leadership Alliance.
Mr. Chung is an active investor in both private and public equity. He also has extensive trading experience in equity and fixed income derivative securities. For the last 19 years, Mr. Chung has worked as an adviser, board member, and at the executive level of several growing companies helping with business development, capital raising, strategic partnerships, and licensing agreements. Currently he serves on the board of 4 private companies.
Mr. Chung worked as a Vice President for both Prudential Securities and SG Cowen in New York City . He was a Managing Director of Pretium Capital Group, Inc. an investment banking firm, and a Portfolio Manager for Caxton Associates LLC, a New York based multi-strategy hedge fund.
Mr. Chung received a BA from Vanderbilt University and MBA from Wake Forest University Babcock Graduate School of Management
Mr. Fisher serves Envision as Vice President of Business Development and its board as Corporate Secretary. He comes to Envision with extensive investment experience and has been involved in capital raises and M&A transactions with a cumulative value of $1B. Previously, Mr. Fisher was an investment team-member of H.I.G. Growth Partners, the growth investing affiliate of H.I.G. Capital, and started his career as an Investment Banking Analyst at Stephens, Inc. .
From 2014 to 2016, Mr. Fisher served as a consultant to the executive teams of several leading healthcare institutions and biotechnology companies including the business development team at the Children’s Hospital of Philadelphia, Sage Therapeutics, and Amicus Therapeutics. He also served as Co-President of Penn Biotech Group Healthcare Consulting – a 200+ member consultancy that provides strategic and commercial consulting services to leading companies in healthcare.
Mr. Fisher holds degrees in Finance and Management from the McIntire School of Commerce at the University of Virginia, and an MBA, with a concentration in Healthcare Management, from the Wharton School at the University of Pennsylvania. Mr. Fisher received a Kaiser and Wharton Fellowship from the University of Pennsylvania.